Billionaire Ken Griffin Sold Amazon and Nvidia but Quietly Loaded Up on This Healthcare Giant

Citadel Advisors increased its stake in Intuitive Surgical by 30.3% in Q1, signaling confidence despite a 20% share decline over the past 12 months. The article cites rising competition from Medtronic and Johnson & Johnson, lower-margin product introductions, and tariff pressure, but argues Intuitive still has a wide moat, strong growth, and a large addressable market. At 39.7x forward earnings versus 17.4x for healthcare, the stock remains expensive but is presented as a long-term buy.

Analysis

ISRG looks like a classic “quality de-rating” setup where the market is pricing near-term margin noise as if it were a structural slowdown. The more interesting second-order effect is that a scaled installed base becomes a defensive flywheel: once hospitals standardize around one platform, competitors must win not just on hardware specs but on training, workflow integration, and service economics, which slows share capture materially even after regulatory clearance.

The competitive threat is real, but likely changes the mix of growth rather than the endpoint. New entrants can pressure headline procedure growth, yet they may also expand the overall robotic surgery category by normalizing adoption, which could ultimately lift the whole market and preserve ISRG’s share of recurring instrument/accessory spend. The near-term margin compression from lower-priced system rollouts is the key variable; that pain is front-loaded, while the monetization of recurring consumables is delayed but much larger in present value terms.

Tariff exposure looks more like a timing issue than a thesis breaker, because the company has pricing power concentrated in a sticky customer base. The more relevant risk is not tariffs themselves, but whether management uses them as an excuse to slow investment in next-generation platforms, which would cede narrative momentum to MDT and JNJ. If AI-assisted planning and workflow software meaningfully improve utilization, ISRG can re-rate from a pure hardware multiple toward a platform multiple over the next 12-24 months.

The consensus is missing that this is less a “cheap versus expensive” debate and more a duration trade on durable reinvestment. At ~40x forward earnings, the stock only works if investors believe the installed-base annuity accelerates faster than competitive dilution. That makes the setup asymmetric: bad news can compress the multiple further in weeks, but any evidence of accelerating procedure growth or better-than-feared margin resilience can trigger a sharp rerating because positioning is already defensive.

Key Decisions for Investors

• Long ISRG on a 6-12 month horizon via staggered entries on weakness; use a 3-5% initial position and add only if procedure growth and margin commentary stabilize, targeting a 15-20% upside rerating if the market stops pricing in a structural slowdown.
• Pair trade: long ISRG / short MDT for the next 3-6 months. The long leg owns the higher-quality installed-base annuity, while the short leg expresses the risk that competing robotic platforms face longer adoption ramps and weaker recurring economics.
• If volatility remains elevated, express bullishness in ISRG through call spreads rather than stock: buy 12-18 month calls financed with higher strikes to capture rerating upside while limiting multiple-compression risk from another tariff or margin miss.
• Avoid chasing JNJ or MDT solely on competitive headlines; use them as hedges rather than outright longs until there is evidence of meaningful procedure conversion, since regulatory wins do not automatically translate into economic share.
• For tactically minded accounts, wait for the next earnings print or channel-check confirmation before adding. The stock can still de-rate another 5-10% on near-term margin concern, but that would improve the long/dated-call reward profile materially.